52.50p+0.00 (+0.00%)08 Dec 2021, 10:01
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Jump to:

Verici Dx PLC Fundamentals

Company NameVerici Dx PLCLast Updated2021-12-08
IndustryDiagnostics & ResearchSectorHealthcare
Shares in Issue141.748 mMarket Cap£74.42 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS0EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0Debt Equity Ratio0
Asset Equity Ratio1.0336Cash Equity Ratio0.8462
Quick Ratio25.5959Current Ratio25.96
Price To Book Value0ROCE0

Verici Dx PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Verici Dx PLC Company Financials

Assets2020
Tangible Assets$464,042.00
Intangible Assets$1.77 m
Investments0
Total Fixed Assets$2.23 m
Stocks0
Debtors$120,678.00
Cash & Equivalents$17.75 m
Other Assets0
Total Assets$20.31 m
Liabilities2020
Creditors within 1 year$681,890.00
Creditors after 1 year0
Other Liabilities0
Total Liabilities$681,890.00
Net assets$19.62 m
Equity2020
Called up share capital$181,614.00
Share Premium$20.35 m
Profit / Loss0
Other Equity$19.62 m
Preference & Minorities0
Total Capital Employed$19.62 m
Ratios2020
Debt Ratio0
Debt-to-Equity0
Assets / Equity1.0336
Cash / Equity0.8462
EPS0
Cash Flow2020
Cash from operating activities0
Cashflow before financing0
Increase in Cash0
Income2020
Turnover0
Cost of sales0
Gross Profit0
Operating Profit0
Pre-Tax profit0

Verici Dx PLC Company Background

SectorHealthcare
ActivitiesVerici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies which will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialisation: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection ("EAR"); and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels.
Latest Interim Date7 Sep 2021
Latest Fiscal Year End Date14 Apr 2021

Verici Dx PLC Directors

AppointedNamePosition
2021-04-15Mr. Julian BainesNon-Executive Director,Chairman
2021-04-15Sir Ian James Carruthers OBENon-Executive Director,Senior Independent Non-Executive Director
2021-04-15Mr. James McCulloughNon-Executive Director
2021-07-01Dr. Barbara MurphyNon-Executive Director
2021-04-15Ms. Sara BarringtonExecutive Director,Chief Executive Officer

Verici Dx PLC Contact Details

Company NameVerici Dx PLC
Address19 Stanwell Road, Avon House, Cardiff, CF64 2EZ
Telephone+44 2920710570
Websitehttps://www.vericidx.com

Verici Dx PLC Advisors